Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer At Esmo Asia Virtual Oncology Week 2021

11/20/2021 | 06:00am EST

Exelixis, Inc. announced detailed results from the first planned analysis of COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX?) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). New results presented during the 2021 ESMO Virtual Plenary include detailed data for a prespecified interim analysis for the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population, which was conducted at the same time as the primary analysis for PFS in the PITT population. At a median follow-up of 13.6 months, the interim OS analysis in the ITT population showed a trend that favored cabozantinib in combination with atezolizumab but did not reach statistical significance (HR: 0.90; 96% CI: 0.69-1.18; P=0.438). Median OS was 15.4 months for cabozantinib in combination with atezolizumab (n=432) versus 15.5 months for sorafenib (n=217). The trial is continuing as planned to the final analysis of OS, anticipated in early 2022. In an interim analysis of the secondary endpoint of PFS per RECIST 1.1 by BIRC performed to determine the contribution of cabozantinib to the combination with atezolizumab, cabozantinib monotherapy reduced the risk of disease progression or death in the ITT population by 29% versus sorafenib (HR: 0.71; 99% CI: 0.51-1.01; P=0.0107; pre-specified critical p-value of 0.00451). Median PFS was 5.8 months for cabozantinib (n=188) versus 4.3 months for sorafenib (n=217). Objective response rates per RECIST 1.1 by BIRC in the ITT population were 11% for cabozantinib in combination with atezolizumab, 3.7% for sorafenib and 6.4% for cabozantinib monotherapy. Disease control rates (complete response + partial response + stable disease) were 78%, 65% and 84%, respectively.


ę S&P Capital IQ 2021
All news about EXELIXIS, INC.
01/19Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to ..
MT
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
BU
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
CI
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
PU
01/10EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/10Exelixis Expects Net Product Revenue of $300 Million for Q4, $1.08 Billion for Full-Yea..
MT
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
BU
01/09Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter a..
CI
01/06Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Ful..
MT
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
BU
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 342 M - -
Net income 2021 165 M - -
Net cash 2021 1 019 M - -
P/E ratio 2021 33,7x
Yield 2021 -
Capitalization 5 512 M 5 512 M -
EV / Sales 2021 3,35x
EV / Sales 2022 2,70x
Nbr of Employees 773
Free-Float 97,9%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 17,42 $
Average target price 28,85 $
Spread / Average Target 65,6%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-1.97%5 512
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325